ACRS vs WVE
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ACRS · Aclaris Therapeutics$3.90 ▲ 8.03%
WVE · Wave Life Sciences$3.37 ▲ 4.50%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ACRS +83.1%
- WVE -52.2%
Head to head
| Metric | ACRS | WVE |
|---|---|---|
| Price | $3.90 | $3.37 |
| Change today | ▲ 8.03% | ▲ 4.50% |
| Market cap | $618.59M | $663.68M |
| Return, 3 months | -33.9% | -44.6% |
| Return, year to date | +29.6% | -80.2% |
| Return, 1 year | +68.1% | -57.2% |
| P/E (TTM) | – | – |
| P/B | 3.7 | 1.7 |
| P/E percentile vs own 5y | 41st | 64th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | -8.3% | +72.9% |
| Net profit growth (YoY) | -39.4% | -15.0% |
| Gross margin | 12.9% | – |
| Operating margin | -1,040.4% | -320.9% |
| Net margin | -921.5% | -296.9% |
| Return on equity | -59.1% | -80.0% |
| Analyst target vs. price | +216.2% | +410.3% |
| Analyst buy share | 100% | 94% |
| RSI (14) | 47 | 44 |
| 30-day volatility | 95.3% | 64.8% |
| Max drawdown, 1 year | -49.8% | -85.5% |
| Trend read | Leaning bullish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- WVE is the largest of the group by market value.
- ACRS has returned the most over the past year.
- WVE is growing revenue fastest.
- WVE keeps the most profit per dollar of sales.
- WVE has been the calmest stock over the last 30 days.